Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.

Date publication

octobre 2018

Journal

Cancer chemotherapy and pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ZANETTA Sylvie

Tous les auteurs :
Martin N, Isambert N, Gomez-Roca C, Goeldner RG, Zanetta S, Sadrolhefazi B, de Mont-Serrat H, Campone M, Delord JP

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30350178

Résumé

Trastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occurs. Afatinib, an irreversible oral ErbB family blocker, shows clinical activity in trastuzumab-refractory HER2-positive metastatic breast cancer.

Mots clés

Afatinib, Diarrhea, HER2-positive cancer, Trastuzumab

Référence

Cancer Chemother. Pharmacol.. 2018 Oct 22;: